John F. Crowley

John F. Crowley is the Chairman and CEO of Amicus Therapeutics, Inc., a global biotechnology company engaged in the discovery, development and commercialization of novel treatments for persons living with rare and orphan diseases.

Mr. Crowley’s involvement with biotechnology stems from the 1998 diagnosis of two of his children with Pompe disease—a severe and often fatal neuromuscular disorder. In his drive to find a cure for them, he left his position at Bristol-Myers Squibb and became an entrepreneur as the Co-founder, President and CEO of Novazyme Pharmaceuticals, a biotech start-up conducting research on a new experimental treatment for Pompe disease (which he credits as ultimately saving his children’s lives). In 2001, Novazyme was acquired by Genzyme Corporation and Mr. Crowley continued to play a lead role in the development of a drug for Pompe disease as Senior Vice President, Genzyme Therapeutics.

Mr. Crowley served from 2005-2016 as a commissioned officer in the U.S. Navy Reserve, assigned to the Joint Special Operations Command and is a veteran of the global war on terrorism, with service in Afghanistan. He graduated with a BS in Foreign Service from Georgetown University, and earned a JD from the University of Notre Dame Law School and an MBA from Harvard Business School. The Crowley family was the recipient of the 2011 Family Exemplar Award from the University of Notre Dame. He is also a member of the University Council on Science & Technology at Notre Dame. Mr. Crowley served previously as the National Chairman of the Make A Wish Foundation of America and is a founding Board member of the Global Genes Project. Mr. Crowley is a Henry Crown Fellow at the Aspen Institute.